DolCas-Tenshi Bioceuticals has launched its debut nutraceutical formula of its new joint venture. The group, comprised of DolCas Biotech and Tenshi Kaizen Private, created the new formulation Fortiquin, to target male sexual health.
Fortiquin is a five-ingredient, patent-pending blend of herbal extracts and nutrients has been carefully designed to support sexual stamina and overall wellbeing in healthy men experiencing problems with sexual performance.
Derived from the wisdom of the Ayurvedic medical tradition, Fortiquin is composed of four botanicals: mucuna, cynara, trigonella and ashwanghanda, combined with the amino acid L-arginine.
The blend works in synergy to nourish and balance multiple systems for the overall enhancement of men’s health and, more specifically, sexual stamina. Comprehensive clinical studies are ongoing.
The symbiotic blend of extracts, in proprietary ratios, are standardised to their bioflavonoid and saponin contents. These two classes of phytochemicals are commonly touted for their therapeutic activity, including their effects on the reproductive, vascular and nervous systems.
Shavon Jackson-Michel, Director of Medical and Scientific Affairs at DolCas-Tenshi, said: “The individual herbs coexist as clean-label extracts, rather than powders, delivering not only an enriched profile of the phytochemicals most associated with their functionality and organ affinity, but also ensuring consistent quality from batch to batch.”
“DolCas-Tenshi is attentive to the drive for increased standardisation of quality for all aspects of developing natural sexual health products,” said Vivek A Parachur, co-founder and CEO of Olene Life Sciences, developer and manufacturer of Fortiquin.
Parachur added: “This encompasses sourcing, storage, and proper clinical assessment of bioactivity and efficacy. Lack of such attention can leave the consumer with little confidence in product effectiveness. Pursuing the highest level of consumer confidence in the product is where Fortiquin stands out.”
The release of a publication reviewing the formula's clinical effects on sexual function in men is expected in the late spring of this year. The uniqueness of Fortiquin’s composition potentially avails it to other clinical functions, such as sports performance and menopausal support.
Dolcas-Tenshi plans to further investigate Fortiquin’s applicability for these additional health areas.
The company will launch the all-natural, vegan complex at Vitafoods Europe in Geneva on May 7-9, 2018, booth F200.
